Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-549-0
CAS number: 84-65-1
Both in vivo studies conducted by the NTP USA are still under discussion. Under the conditions of these 2-year feed studies, there was some evidence of carcinogenic activity of Anthraquinone in M/F F344/N rats and in M/F B6C3F1 mice (The National Toxicology Program, NIH Publication No. 05-3953, 2005).According to the results of the NTP USA studies, the Anthraquinone should be considered as carcinogen, category 2 and assigned the symbol T and the risk phrase R45. However, the available data raise concern and further experiments are necessary (The Draft Assessment Report – Anthraquinone, Belgium, 2006).According to the published data by Butterworth (2004), the presence of 9-nitroanthracene used in the NTP cancer bioassays was responsible for the carcinogenic effects as a result of its genotoxic activity; however, the evidence for this was only indirect (The Draft Assessment Report – Anthraquinone, Belgium, 2006).Dr. J. A. Cook in his Letter from April 7, 2010 (attached to this CSR, Annex 2) strongly suggested that Anthraquinone, CAS #84-65-1 was a non-carcinogen, mainly due to the fact that the test article yielding positive results in the NTP Report contained 9-nitroanthracene contamination which confounded interpretation of the studies, while pure Anthraquinone was negative. Furthermore, Anthraquinone was predicted to be a non-carcinogen in most of the mechanism-mediated and structure-activity relationship evaluations, and results of in vitro and in vivo studies were inconclusive. Hence, based on the Letter of Dr. Cook, based on the ongoing discussions, recent knowledge, uncertainties involved in the interpretation of the test results, and considering controversial data available from in vitro and in vivo carcinogenicity studies, Anthraquinone is considered as a non-carcinogenic substance.The weight of evidence determination that Anthraquinone is not carcinogen was prepared by SIEF member Chemical Products Corporation (see attachement).
to the EC criteria for classification and labelling requirements for
dangerous substances and mixtures the test substance Anthraquinone does
not have to be classified for carcinogenicity.
did not provide carcinogenicity studies.The
studies from NTP
Technical report on the toxicology and carcinogenesis studies of
Anthraquinone (CAS No.84-65-1)
in F344/N rats and B6C3F1 mice (feed studies) (The
National Toxicology Program, NIH
Publication No. 05-3953, 2005)
included in this report.
50 M and 50 F F344/N rats were fed diets containing 469, 938, 1,875, or
3,750 ppm for 105 weeks (2 year). Survival of all M was similar, but
survival of exposed F was greater than that of the controls. Mean body
weights of exposed M during the latter part of the study and mean body
weights of exposed F throughout most of the study were less than those
of the controls. Feed consumption by exposed groups was similar to that
by the controls. The incidences of renal tubule adenoma and renal tubule
adenoma or carcinoma (combined) occurred with positive trends and were
increased in all exposed F. The incidences of renal tubule adenoma in
all exposed M exceeded the historical control range, and the incidence
was significantly increased in the 938 ppm. Increased incidences of
nonneoplastic lesions of the kidney associated with Anthraquinone
exposure included hyaline droplet accumulation, pigmentation, and
mineralization in the renal medulla and transitional epithelial
hyperplasia in M/F and renal tubule hyperplasia in F. Incidences
of nephropathy were increased in F, and severities of nephropathy were
increased in M. At 3 months, the concentration of α2u-globulin in the
kidney of 3,750 ppm M was greater than that in the control group. The
incidence of urinary bladder transitional epithelial papilloma was
significantly greater in 1,875 ppm M than in the control group, and the
incidences in groups M exposed to 938 ppm or greater exceeded the
historical control range. There were positive trends in the incidences
of transitional epithelial hyperplasia and papilloma or carcinoma
(combined) of the urinary bladder in F. The incidences of hepatocellular
adenoma or carcinoma (combined) were slightly increased in exposed M/F;
the incidences in groups of F exposed to 938 ppm or greater exceeded the
historical control range. The incidences of several nonneoplastic
follicular cell hypertrophy was present in all M/F exposed to 3,750 ppm
or greater. Incidences of inflammation and transitional cell hyperplasia
in the urinary bladder of 30,000 ppm F were greater than those in the
National Toxicology Program,NIH Publication No. 05-3953,2005).
50 M and 50 F B6C3F1 mice were fed diets containing 0, 833, 2,500, or
7,500 ppm (equivalent to average daily doses of approximately 90, 265,
or 825 mg/kg to M and 80, 235, or 745 mg/kg to F) for 105 weeks.
Survival was less for 7,500 ppm M than for the control group. Mean body
weights of 7,500 ppm M during the last 6 months of the study and mean
body weights of 7,500 ppm F at the end of the study were less than those
of the control groups. Feed consumption was similar in all groups of
M/F. Incidences of hepatocellular neoplasms (including multiple
neoplasms) increased with a positive trend in M/F, and the incidences
were increased in all exposed groups. Incidences of hepatoblastoma were
significantly increased in males exposed to 2,500 or 7,500 ppm. The
incidences of several nonneoplastic lesions of the liver were increased
in exposed mice. There was a marginal increase in the incidences of
neoplasms of thyroid gland follicular cells in M/F. Incidences of
intracytoplasmic inclusion body of the urinary bladder and hematopoietic
cell proliferation of the spleen in M/F and thyroid gland follicular
cell hyperplasia and kidney pigmentation in M were greater in exposed
groups than in the controls (The
National Toxicology Program,NIH Publication No. 05-3953,2005).
final reports of the 2 carcinogenicity studies (above), conducted by the
NTP USA, with Anthraquinone in rats and mice are still under discussion.
According to the published data by Butterworth (2004), the presence of
9-nitroanthracene used in the NTP cancer bioassays was responsible for
the carcinogenic effects as a result of its genotoxic activity; the
evidence for this is only indirect (The Draft Assessment Report –
Anthraquinone, Belgium, 2006).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
За да гарантираме, че се възползвате максимално от функциите на нашия уебсайт, сме въвели „бисквитки“.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again